Clinical progress of selective cyclin-dependent kinase (CDK) inhibitors

被引:13
作者
Misra, RN [1 ]
机构
[1] NCI, Pharmaceut Resources Branch, Dev Therapeut Program, Div Canc Therapeut & Diag,NIH, Rockville, MD 20852 USA
关键词
D O I
10.1358/dof.2006.031.01.953584
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclin-dependent kinases (CDKs) are cellular proteins that control cell proliferation. Due to their central role in controlling cell growth and to their dysregulation in many cancers, CDKs have become an important molecular target for oncology drug development programs. The clinical progress of the first-generation compound alvocidib and three second-generation inhibitors (SNS-032, seliciclib and Ro-4584820) is reviewed here. In order to fully evaluate the clinical utility of these agents, dosing schedules and routes of administration continue to be optimized with the goals of minimizing toxicities and maximizing exposure. To date, single-agent phase II efficacy trials in cancer patients using alvocidib have been disappointing, possibly due to dosing limitations resulting from competing toxicities. Recent clinical results, however, indicate that alvocidib may still find niche utilities as single-agent therapy employing finely tailored dosing schedules for particularly susceptible cancers, such as chronic lymphocytic leukemia (CLL). Evaluation of second-generation compounds with greater potency, reduced toxicity and oral activity is continuing in single-agent trials. Clinical applications for combinations with other cytotoxic agents are also being pursued for both alvocidib and the second-generation agents. The clinical role of these agents continues to be explored, although the general clinical validation of the target in cancer therapy is possibly still several years away. In fact, these agents are more likely to be used clinically in combination with other cytotoxic agents than as stand-alone therapy.
引用
收藏
页码:43 / 52
页数:10
相关论文
共 94 条
  • [1] Phase II study of flavopiridol in patients with advanced colorectal cancer
    Aklilu, M
    Kindler, HL
    Donehower, RC
    Mani, S
    Vokes, EE
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (08) : 1270 - 1273
  • [2] BARTKOVITZ D, 2005, 230 ACS NAT M AUG 28
  • [3] Clinical anticancer drug development: targeting the cyclin-dependent kinases
    Benson, C
    Kaye, S
    Workman, P
    Garrett, M
    Walton, M
    de Bono, J
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (01) : 7 - 12
  • [4] BENSON C, 2002, P AM ASS CANC RES AA, V43
  • [5] BENSON C, 2003, P AM SOC CLIN ONCOL, V22
  • [6] BIBLE KC, 2003, P AM SOC CLIN ONCOL, V22
  • [7] Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
    Burdette-Radoux, S
    Tozer, RG
    Lohmann, RC
    Quirt, I
    Ernst, DS
    Walsh, W
    Wainman, N
    Colevas, AD
    Eisenhauer, EA
    [J]. INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 315 - 322
  • [8] Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from cancer and leukemia group B study 19805
    Byrd, JC
    Peterson, BL
    Gabrilove, J
    Odenike, OM
    Grever, MR
    Rai, K
    Larson, RA
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (11) : 4176 - 4181
  • [9] Carlson BA, 1996, CANCER RES, V56, P2973
  • [10] CARLSON BA, 1996, P AM ASS CANC RES AA, V37